Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors

Next Previous
Trial Profile

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RMC-5552 (Primary)
  • Indications Head and neck cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors REVOLUTION Medicines

Most Recent Events

  • 15 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 16 Feb 2024 Status changed from recruiting to active, no longer recruiting.
  • 04 Oct 2023 According to a REVOLUTION Medicines media release, data from this study will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Triple Meeting) in Boston, Massachusetts, to be held October 11-15, and the 2023 European Society for Medical Oncology Congress (ESMO) in Madrid, Spain, to be held October 20-24.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top